Treatment-resistant depression
Treatment-resistant depression, or TRD, is depression that has not improved after two or more antidepressants, each taken at an adequate dose for long enough to work. It describes how the illness has responded so far, not a separate diagnosis.
Also called: TRD, Medication-resistant depression.
Written by Alena Kozlova, PhD, from published studies and prescribing information.
Definition medically reviewed by Dr. Jason Tan, Consultant Psychiatrist, on November 11, 2026, this definition only. Next review: November 11, 2027.
What qualifies you for treatment-resistant depression?
Two antidepressants that did not work, each at a full dose for long enough. NIMH puts that wait at 4 to 8 weeks, and adds that sleep, appetite and concentration often improve before mood lifts. The US label for esketamine nasal spray (Spravato) describes its trial patients the same way: adults who had not responded adequately to at least two different antidepressants of adequate dose and duration in the current episode. By that definition a medication you stopped in the first week, or that was never raised past the starting dose, is not one of the two.
There is no blood test for it. The count is a judgement your prescriber makes with you, so what you can show them about each medication decides how it is counted.
Is TRD a lifelong condition?
For most people, no. STAR*D, the US trial of what to do after a first antidepressant fails, followed 3,671 outpatients through up to four steps of treatment. It counted from the first medication, so the steps that match this page are the third and the fourth: remission there was 13.7% and 13.0%, about one in seven, against 36.8% at the first step and 30.6% at the second.
So the odds fall with each step, and a chance stays on the table at each one. Across all four steps 67% of the people in the trial reached remission at some point, most of them in the first two. The same report found that people who needed more steps relapsed more often afterwards, which is why what you do after you feel better counts as much as getting there.
Why do some people have treatment-resistant depression?
Part of what looks like resistance is about how the treatment went, not about the illness. A dose that was never raised, a few weeks that were cut short, or side effects that made a medication hard to keep taking all leave a trial that cannot answer the question. Those are worth going through with your prescriber before anyone adds the label.
The causes of depression itself are not measured in the clinic yet. NIMH says genetic, biological, environmental and psychological factors all play a role, and no test tells you which of them is at work in you.
What do they do for treatment-resistant depression?
Your prescriber weighs these routes against each other, and which comes first depends on what you have already taken.
- Switching to another antidepressant: stopping the one you take and starting a different one, either straight away or with a cross-taper. Ask why the next medicine they name would suit you better than the last.
- Adding a second medicine: Aripiprazole (Abilify) is approved in the US as an adjunctive treatment of major depressive disorder, which means it is added to an antidepressant rather than replacing it. Its label lists akathisia, restlessness, insomnia, constipation, fatigue and blurred vision as the common reactions in that use, and it carries boxed warnings about increased deaths in elderly patients with dementia-related psychosis and about suicidal thoughts and behaviors with antidepressant drugs.
- Esketamine nasal spray: Spravato is approved for treatment-resistant depression in adults, as monotherapy or together with an oral antidepressant. It is available only through a restricted program called a REMS, and you are monitored for at least 2 hours after each session. Its label also tells prescribers to arrange a ride home and to say that driving and anything else needing full alertness waits until the next day, after a night of restful sleep, so each session takes a day to plan. The boxed warning covers sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors.
- Repetitive transcranial magnetic stimulation: A magnet placed on the scalp, in daily sessions 5 days a week for 4 to 6 weeks, by NIMH. The side effects it lists are discomfort where the magnet sits, tingling or contraction of scalp, jaw or face muscles, mild headaches, brief lightheadedness and dizziness. NIMH says strong clinical evidence supports rTMS for reducing depressive symptoms.
- ECT: Electroconvulsive therapy is given three times a week until symptoms improve, usually within 6 to 12 treatments, and NIMH calls it the gold standard among brain stimulation treatments. Common side effects are headaches, upset stomach, muscle aches, memory loss and disorientation or confusion, and memory problems are more common with the bilateral form than with the one-sided form.
- Vagus nerve stimulation: the slowest of the options to show itself. NIMH says it may be several months before you notice a benefit, and that not all people respond, so agree with your prescriber in advance how long you will give it and what you will both watch.
What to do when TMS does not work?
Not everyone responds, and the other routes stay open: ECT, esketamine, vagus nerve stimulation, a switch, or a second medicine added to the one you take. Ask your prescriber what was measured during the course of rTMS, how far your score moved, and what they would try next.
What to do
Bring one list to your prescriber: every antidepressant you have taken, the highest dose you reached, how many weeks you stayed there, and what changed. That list is what decides whether a medication counts as an adequate trial. Ask what the next step would be and how you will both tell whether it worked, and call them if your mood drops while you wait. If you are having thoughts of harming yourself, contact a crisis line straight away: call or text 988 in the US, or your local emergency number.
Find mental health help in the US
How withClaro helps
- Log how you feel each day, next to the dose you took
- Share a PDF report with your prescriber before the appointment
- Reminders, so a trial is not cut short by missed doses
Get the withClaro app on the App Store
Related terms
Sources
- U.S. Food and Drug Administration. Spravato (esketamine) nasal spray: prescribing information. FDA / DailyMed, 2026.
- U.S. Food and Drug Administration. Abilify (aripiprazole) tablets: prescribing information. FDA / DailyMed, 2025.
- National Institute of Mental Health. Brain stimulation therapies. NIMH (nimh.nih.gov), 2024.
- Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 2006.
- National Institute of Mental Health. Depression. NIMH (nimh.nih.gov), 2024.
- National Institute of Mental Health. Depression (NIH Publication No. 24-MH-8079). NIMH (nimh.nih.gov), 2024.
All glossary terms